Kronos Bio Stock Performance
| KRON Stock | USD 0.89 0.01 1.11% |
The company secures a Beta (Market Risk) of 0.4, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Kronos Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Kronos Bio is expected to be smaller as well. At this point, Kronos Bio has a negative expected return of -0.13%. Please make sure to verify Kronos Bio's total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Kronos Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kronos Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
Last Split Factor 3:2 | Last Split Date 2003-11-03 |
1 | After Plunging -5.53 percent in 4 Weeks, Heres Why the Trend Might Reverse for Kronos Bio | 09/10/2024 |
2 | Acquisition by Tanen David M of 34000 shares of Kronos Bio at 1.48 subject to Rule 16b-3 | 09/13/2024 |
3 | Disposition of tradable shares by Frisbee Allison of Kronos Bio subject to Rule 16b-3 | 09/18/2024 |
4 | Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjgrens Disease | 10/07/2024 |
5 | Piper Sandler Reaffirms Overweight Rating for Kronos Bio | 10/11/2024 |
6 | Acquisition by Charles Lin of 72900 shares of Kronos Bio at 0.96 subject to Rule 16b-3 | 10/15/2024 |
7 | Grecian Delight Kronos Donates Over 150,000 Servings of Food and Essential Supplies to Hurricane Relief Efforts | 10/17/2024 |
8 | Kronos Worldwide Inc Shares Up 4.08 percent on Nov 4 | 11/04/2024 |
9 | Aprea Therapeutics, Inc. Reports Q3 Loss, Lags Revenue Estimates | 11/07/2024 |
10 | Human Capital Management Market Expected to Reach USD 57.8 Billion by 2032 Increasing Demand for Streamlined Workforce Management Drives Growth Research by SS I... | 11/08/2024 |
11 | Kronos Worldwide Inc Trading Down 3.34 percent on Nov 12 | 11/12/2024 |
12 | Kronos Bio shares downgraded to hold by TD Cowen | 11/14/2024 |
| Begin Period Cash Flow | 78 M |
Kronos |
Kronos Bio Relative Risk vs. Return Landscape
If you would invest 100.00 in Kronos Bio on August 28, 2024 and sell it today you would lose (11.00) from holding Kronos Bio or give up 11.0% of portfolio value over 90 days. Kronos Bio is currently does not generate positive expected returns and assumes 3.3923% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Kronos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kronos Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kronos Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kronos Bio, and traders can use it to determine the average amount a Kronos Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0377
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KRON |
Estimated Market Risk
| 3.39 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kronos Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kronos Bio by adding Kronos Bio to a well-diversified portfolio.
Kronos Bio Fundamentals Growth
Kronos Stock prices reflect investors' perceptions of the future prospects and financial health of Kronos Bio, and Kronos Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kronos Stock performance.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (6.49) % | ||||
| Current Valuation | (44.57 M) | ||||
| Shares Outstanding | 60.34 M | ||||
| Price To Book | 0.49 X | ||||
| Price To Sales | 6.48 X | ||||
| Revenue | 6.29 M | ||||
| EBITDA | (121.83 M) | ||||
| Net Income | (112.67 M) | ||||
| Cash And Equivalents | 267.89 M | ||||
| Cash Per Share | 4.72 X | ||||
| Total Debt | 28.27 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 15.07 X | ||||
| Book Value Per Share | 2.70 X | ||||
| Cash Flow From Operations | (78.58 M) | ||||
| Earnings Per Share | (1.43) X | ||||
| Market Capitalization | 54.49 M | ||||
| Total Asset | 213.28 M | ||||
| Retained Earnings | (508.86 M) | ||||
| Working Capital | 154.08 M | ||||
About Kronos Bio Performance
By examining Kronos Bio's fundamental ratios, stakeholders can obtain critical insights into Kronos Bio's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Kronos Bio is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (760.64) | (798.67) | |
| Return On Tangible Assets | (0.53) | (0.55) | |
| Return On Capital Employed | (0.65) | (0.68) | |
| Return On Assets | (0.53) | (0.55) | |
| Return On Equity | (0.71) | (0.67) |
Things to note about Kronos Bio performance evaluation
Checking the ongoing alerts about Kronos Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kronos Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kronos Bio generated a negative expected return over the last 90 days | |
| Kronos Bio has some characteristics of a very speculative penny stock | |
| Kronos Bio has high historical volatility and very poor performance | |
| Kronos Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 6.29 M. Net Loss for the year was (112.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kronos Bio currently holds about 267.89 M in cash with (78.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Kronos Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 27.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from investing.com: Kronos Bio shares downgraded to hold by TD Cowen |
- Analyzing Kronos Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kronos Bio's stock is overvalued or undervalued compared to its peers.
- Examining Kronos Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kronos Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kronos Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kronos Bio's stock. These opinions can provide insight into Kronos Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share 0.143 | Quarterly Revenue Growth 0.442 | Return On Assets (0.28) | Return On Equity (0.63) |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.